Moab Capital Partners Llc increased Nam Tai Ppty Inc (NTP) stake by 346.27% reported in 2018Q4 SEC filing. Moab Capital Partners Llc acquired 83,940 shares as Nam Tai Ppty Inc (NTP)’s stock rose 3.14%. The Moab Capital Partners Llc holds 108,181 shares with $939,000 value, up from 24,241 last quarter. Nam Tai Ppty Inc now has $378.02 million valuation. The stock increased 2.03% or $0.2 during the last trading session, reaching $10.06. About 32,301 shares traded or 64.65% up from the average. Nam Tai Property Inc. (NYSE:NTP) has declined 30.62% since March 21, 2018 and is downtrending. It has underperformed by 34.99% the S&P500. Some Historical NTP News: 30/04/2018 – Nam Tai Property 1Q Adj Loss/Shr 24c; 10/04/2018 – Nam Tai Property Entered Into $184M Financing Package for Construction of Nam Tai Inno Park-; 31/05/2018 – NAM TAI PROPERTY INC. Announces the Receipt of Construction Permits for Nam Tai lnno Park; 16/03/2018 Nam Tai Property Inc. Filed Annual Report on Form 20-F for 2017 with SEC on March 9, 2018; 10/04/2018 – Nam Tai Property Inc. Announces Financing Package for the Construction of Nam Tai lnno Park and Date of Earnings Release; 30/04/2018 – Nam Tai Property 1Q EPS 7c; 23/05/2018 – Nam Tai Property Inc. Announces the Selection of Main Contractors for Nam Tai lnno Park; 10/04/2018 – NAM TAI PROPERTY – FINANCING PACKAGE CONSISTS OF FIXED ASSET LOAN AGREEMENT BETWEEN CCB AND ZASTRON SHENZHEN; 10/04/2018 – Nam Tai Property Inc. Announces Financing Package for the Construction of Nam Tai Inno Park and Date of Earnings Release; 10/04/2018 – NAM TAI PROPERTY INC – ENTERED INTO US$184 MLN FINANCING PACKAGE FOR CONSTRUCTION OF NAM TAI INNO PARK WITH CHINA CONSTRUCTION BANK CORPORATION
Analysts expect InflaRx N.V. (NASDAQ:IFRX) to report $-0.44 EPS on April, 4.After having $-0.31 EPS previously, InflaRx N.V.’s analysts see 41.94% EPS growth. The stock decreased 1.95% or $0.92 during the last trading session, reaching $46.16. About 222,253 shares traded or 95.14% up from the average. InflaRx N.V. (NASDAQ:IFRX) has risen 39.39% since March 21, 2018 and is uptrending. It has outperformed by 35.02% the S&P500. Some Historical IFRX News: 17/05/2018 – InflaRx 1Q Loss/Shr EUR0.04; 08/03/2018 – INFLARX ANNOUNCES FIRST PATIENT ENROLLED IN PHASE llB TRIAL WITH LEAD CANDIDATE IFX-1 IN HIDRADENITIS SUPPURATIVA; 08/03/2018 – lnflaRx announces first patient enrolled in Phase llb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 03/05/2018 – INFLARX PRIMARY, SECONDARY OFFERINGS PRICES AT $34.00 PER SHARE; 08/03/2018 InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa; 08/05/2018 – InflaRx N.V. Announces Closing of Primary and Secondary Offering of Common Shrs; 08/05/2018 – INFLARX N.V. REPORTS CLOSING OF PRIMARY, SECONDARY OFFERING; 17/05/2018 – InflaRx 1Q Loss EUR10.3M; 29/03/2018 – lnflaRx Full Year 2017 Financial & Operating Results; 29/03/2018 – InflaRx FY Loss/Shr EUR2.6
More notable recent InflaRx N.V. (NASDAQ:IFRX) news were published by: Nasdaq.com which released: “AC Immune Reports Full-Year 2018 Financial Results and Provides Business Update – Nasdaq” on March 21, 2019, also Nasdaq.com with their article: “Technology Sector Update for 03/20/2019: TDC,SMAR,TME – Nasdaq” published on March 20, 2019, Nasdaq.com published: “Mechel Reports the FY2018 Financial Results – Nasdaq” on March 21, 2019. More interesting news about InflaRx N.V. (NASDAQ:IFRX) were released by: Nasdaq.com and their article: “WENDEL : 2018 Full-Year Results – Nasdaq” published on March 21, 2019 as well as Nasdaq.com‘s news article titled: “Technology Sector Update for 03/20/2019: SMAR, TME, MSFT, AAPL, IBM, CSCO, GOOG – Nasdaq” with publication date: March 20, 2019.
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. The company has market cap of $1.19 billion. The Company’s C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. It currently has negative earnings. The company’s lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.
More notable recent Nam Tai Property Inc. (NYSE:NTP) news were published by: Businesswire.com which released: “A10 Networks DDoS Threat Intelligence Finds IoT Devices a Growing Part of Global DDoS Weapon Arsenals – Business Wire” on March 05, 2019, also Seekingalpha.com with their article: “Nam Tai Property Is My Top Buy Of 2018 – Seeking Alpha” published on October 27, 2017, Seekingalpha.com published: “Nam Tai: Like Buying Into 1970s’ Silicon Valley – Seeking Alpha” on February 07, 2017. More interesting news about Nam Tai Property Inc. (NYSE:NTP) were released by: Nasdaq.com and their article: “Sunrun Reports Fourth Quarter and Full Year 2018 Financial Results – Nasdaq” published on February 28, 2019 as well as Prnewswire.com‘s news article titled: “NAM TAI PROPERTY INC. Announces the Availability of Updated Real Estate Feasibility Studies – PR Newswire” with publication date: June 22, 2018.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.